Cue Biopharma, Inc.
CUE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.09 | -0.34 | 0.83 |
| FCF Yield | -59.28% | -33.08% | -41.32% | -11.23% |
| EV / EBITDA | -1.27 | -1.89 | -1.37 | -6.59 |
| Quality | ||||
| ROIC | -157.35% | -100.71% | -62.37% | -57.03% |
| Gross Margin | 100.00% | -593.93% | -45.04% | 111.90% |
| Cash Conversion Ratio | 0.89 | 0.79 | 0.79 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | 95.39% | -28.38% | -26.65% | 62.87% |
| Free Cash Flow Growth | 8.92% | 4.80% | -5.60% | -20.13% |
| Safety | ||||
| Net Debt / EBITDA | 0.36 | 0.73 | 0.64 | 1.20 |
| Interest Coverage | -52.14 | -41.89 | -74.56 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -401.33 | 79.35 | -535.15 | 608.61 |